These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 10819579)

  • 1. Efficacy of cancer gene therapy in aging: adenocarcinoma cells engineered to release IL-2 are rejected but do not induce tumor specific immune memory in old mice.
    Provinciali M; Argentati K; Tibaldi A
    Gene Ther; 2000 Apr; 7(7):624-32. PubMed ID: 10819579
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of neutrophils and CD4+ T lymphocytes in the primary and memory response to nonimmunogenic murine mammary adenocarcinoma made immunogenic by IL-2 gene.
    Cavallo F; Giovarelli M; Gulino A; Vacca A; Stoppacciaro A; Modesti A; Forni G
    J Immunol; 1992 Dec; 149(11):3627-35. PubMed ID: 1358974
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Different tumours, transduced with different cytokine genes as G-CSF and IL-2, show inhibition of tumour take through neutrophil activation but differ in T cell functions.
    Stoppacciaro A; Forni G; Colombo MP
    Folia Biol (Praha); 1994; 40(1-2):89-99. PubMed ID: 7525363
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of established pancreatic cancers following specific active immunotherapy with interleukin-2 gene-transduced tumor cells.
    Clary BM; Coveney EC; Philip R; Blazer DG; Morse M; Gilboa E; Lyerly HK
    Cancer Gene Ther; 1997; 4(2):97-104. PubMed ID: 9080118
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CIITA-induced MHC class II expression in mammary adenocarcinoma leads to a Th1 polarization of the tumor microenvironment, tumor rejection, and specific antitumor memory.
    Mortara L; Castellani P; Meazza R; Tosi G; De Lerma Barbaro A; Procopio FA; Comes A; Zardi L; Ferrini S; Accolla RS
    Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3435-43. PubMed ID: 16740768
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Local release of IL-10 by transfected mouse mammary adenocarcinoma cells does not suppress but enhances antitumor reaction and elicits a strong cytotoxic lymphocyte and antibody-dependent immune memory.
    Giovarelli M; Musiani P; Modesti A; Dellabona P; Casorati G; Allione A; Consalvo M; Cavallo F; di Pierro F; De Giovanni C
    J Immunol; 1995 Sep; 155(6):3112-23. PubMed ID: 7673726
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An efficient Th2-type memory follows CD8+ lymphocyte-driven and eosinophil-mediated rejection of a spontaneous mouse mammary adenocarcinoma engineered to release IL-4.
    Pericle F; Giovarelli M; Colombo MP; Ferrari G; Musiani P; Modesti A; Cavallo F; Di Pierro F; Novelli F; Forni G
    J Immunol; 1994 Dec; 153(12):5659-73. PubMed ID: 7989764
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IFN-alpha 1 gene expression into a metastatic murine adenocarcinoma (TS/A) results in CD8+ T cell-mediated tumor rejection and development of antitumor immunity. Comparative studies with IFN-gamma-producing TS/A cells.
    Ferrantini M; Giovarelli M; Modesti A; Musiani P; Modica A; Venditti M; Peretti E; Lollini PL; Nanni P; Forni G
    J Immunol; 1994 Nov; 153(10):4604-15. PubMed ID: 7963533
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IFN-gamma-independent synergistic effects of IL-12 and IL-15 induce anti-tumor immune responses in syngeneic mice.
    Comes A; Di Carlo E; Musiani P; Rosso O; Meazza R; Chiodoni C; Colombo MP; Ferrini S
    Eur J Immunol; 2002 Jul; 32(7):1914-23. PubMed ID: 12115611
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of neutrophils and lymphocytes in inhibition of a mouse mammary adenocarcinoma engineered to release IL-2, IL-4, IL-7, IL-10, IFN-alpha, IFN-gamma, and TNF-alpha.
    Musiani P; Allione A; Modica A; Lollini PL; Giovarelli M; Cavallo F; Belardelli F; Forni G; Modesti A
    Lab Invest; 1996 Jan; 74(1):146-57. PubMed ID: 8569177
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of antitumor immunity by combined immunogene therapy using IL-2 and IL-12 in low antigenic Lewis lung carcinoma.
    Tanaka M; Saijo Y; Sato G; Suzuki T; Tazawa R; Satoh K; Nukiwa T
    Cancer Gene Ther; 2000 Nov; 7(11):1481-90. PubMed ID: 11129290
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 5-Fluorocytosine-induced eradication of murine adenocarcinomas engineered to express the cytosine deaminase suicide gene requires host immune competence and leaves an efficient memory.
    Consalvo M; Mullen CA; Modesti A; Musiani P; Allione A; Cavallo F; Giovarelli M; Forni G
    J Immunol; 1995 May; 154(10):5302-12. PubMed ID: 7730633
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction of immunity in peripheral tissues combined with intracerebral transplantation of interleukin-2-producing cells eliminates established brain tumors.
    Iwadate Y; Yamaura A; Sato Y; Sakiyama S; Tagawa M
    Cancer Res; 2001 Dec; 61(24):8769-74. PubMed ID: 11751397
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
    Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
    Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mice vaccination with interleukin 12-transduced colon cancer cells potentiates rejection of syngeneic non-organ-related tumor cells.
    Adris S; Chuluyan E; Bravo A; Berenstein M; Klein S; Jasnis M; Carbone C; Chernajovsky Y; Podhajcer OL
    Cancer Res; 2000 Dec; 60(23):6696-703. PubMed ID: 11118055
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Irradiated CIITA-positive mammary adenocarcinoma cells act as a potent anti-tumor-preventive vaccine by inducing tumor-specific CD4+ T cell priming and CD8+ T cell effector functions.
    Mortara L; Frangione V; Castellani P; De Lerma Barbaro A; Accolla RS
    Int Immunol; 2009 Jun; 21(6):655-65. PubMed ID: 19395374
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vascular attack by 5,6-dimethylxanthenone-4-acetic acid combined with B7.1 (CD80)-mediated immunotherapy overcomes immune resistance and leads to the eradication of large tumors and multiple tumor foci.
    Kanwar JR; Kanwar RK; Pandey S; Ching LM; Krissansen GW
    Cancer Res; 2001 Mar; 61(5):1948-56. PubMed ID: 11280751
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antitumoral vaccination with granulocyte-macrophage colony-stimulating factor or interleukin-12-expressing DHD/K12 colon adenocarcinoma cells.
    Lechanteur C; Moutschen M; Princen F; Lopez M; Franzen E; Gielen J; Bours V; Merville MP
    Cancer Gene Ther; 2000 May; 7(5):676-82. PubMed ID: 10830715
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Co-expression of B7-1 and ICAM-1 on tumors is required for rejection and the establishment of a memory response.
    Cavallo F; Martin-Fontecha A; Bellone M; Heltai S; Gatti E; Tornaghi P; Freschi M; Forni G; Dellabona P; Casorati G
    Eur J Immunol; 1995 May; 25(5):1154-62. PubMed ID: 7539748
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapy of lung metastases through combined vaccination with carcinoma cells engineered to release IL-13 and IFN-gamma.
    De Giovanni C; Nicoletti G; Landuzzi L; Rossi I; Astolfi A; Ricci C; Di Carlo E; Musiani P; Forni G; Fradelizi D; Nanni P; Lollini PL
    Gene Ther; 2001 Nov; 8(22):1698-704. PubMed ID: 11892837
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.